IONSNMSHealthcare·Biotechnology#17 in industry

Ionis Pharmaceuticals, Inc.

Reports in 2d· 2026-04-29

-11.8% · 90d

$72.23

-1.04 (-1.42%)

News

(2)

April 2026

Apr 23, 20265 days agoDEF 14AHealthcare

IONS Shareholders Vote on Board and Approve Increased Employee Stock Options

IONSIONIS PHARMACEUTICALS INC

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Ionis Pharmaceuticals. It’s essentially the official "playbook" and ballot for the company's 2026 Annual Meeting of Stockholders. Its job is to inform you, the shareholder, about what will be voted on and provide the d

Read summaryView on SEC EDGAR

Apr 23, 20265 days agoARSHealthcare

IONS files annual report detailing financial results and pipeline updates

IONSIONIS PHARMACEUTICALS INC

# 🔥 What This Document Is This is Ionis Pharmaceuticals' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "report card" sent directly to its owners (the shareholders). It’s a comprehensive review that goes beyond the basic financial numbers to explain their business, ach

Read summaryView on SEC EDGAR

Key Data

Market Cap$11.93B

Open$74.00

Prev Close$73.27

Day Range$72.21 – $75.00

52W Range$29.42 – $86.74

Volume2,287,085

P/E (TTM)—

EPS$-2.38

Dividend Yield—

Beta0.40

Profit Margin-40.41%

Revenue Growth-10.30%

Price Target$98.74(+36.7%)

Next Earnings2026-04-29(2d)

Analyst Ratings

Strong Buy24 analysts

Buy 18Hold 6Sell 0

About

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Healthcare · Biotechnology

1,402 employees

www.ionis.com